Zobrazeno 1 - 10
of 240
pro vyhledávání: '"William N William"'
Autor:
Charles Lu, Mehmet Altan, Apar Pataer, Tina Cascone, Annikka Weissferdt, Jianjun Zhang, Boris Sepesi, Ara A Vaporciyan, Marcelo V Negrao, Hai T Tran, Stephen G Swisher, John V Heymach, Don L Gibbons, Brett W Carter, Jack A Roth, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Wayne L Hofstetter, J Jack Lee, Bonnie S Glisson, Myrna C B Godoy, Garrett L Walsh, Jia Wu, Humam Kadara, George R Blumenschein, Heather Y Lin, Nicolas Zhou, William N William, Cheuk H Leung, Frank V Fossella, Anne S Tsao, Jonathan M Kurie, Lauren A Byers, Reza J Mehran, David C Rice, Luisa M Solis Soto
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the efficacy of ne
Externí odkaz:
https://doaj.org/article/6cabe896ecc5458b81684d743e2ba8f9
Autor:
Christine H Chung, Lara A Dunn, Ibrahima Soumaoro, Leonardo Nicacio, Dan P Zandberg, Douglas Adkins, Tanguy Y Seiwert, Nabil F Saba, Lova Sun, Thomas J George, William N William, Kristi Schmidt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/17b76e75d5a34466a55abfaee12a9987
Autor:
Rafael A Schmerling, Antonio C Buzaid, Carolina K Haddad, Fabio AB Schutz, Fabio R Kater, Juliana Pimenta, Fernando Maluf, William N William, Camila Lopes, Dafne R Bromberg, Ana C Oliveira, Ricardo Golmia, Morton Scheinberg
Publikováno v:
Future Science OA, Vol 7, Iss 1 (2021)
Objectives: The presence of autoimmune events were recorded in patients receiving immune checkpoint inhibitors. Materials & Methods: Retrospective study in patients receiving immune checkpoint inhibitors (ICIs) during the period of 2012–2019. Resul
Externí odkaz:
https://doaj.org/article/e47be0c0a15b444fb5acc44d1bd366ff
Autor:
Aline B. Lara Gongora, Gustavo Werutsky, Denis L. Jardim, Angelica Nogueira-Rodrigues, Carlos H. Barrios, Clarissa Mathias, Fernando Maluf, Rachel Riechelmann, Maurício Fraga, Henry Gomes, William N. William, Camilla A. F. Yamada, Gilberto de Castro Jr, Daniela D. Rosa, Andreia C. de Melo, Raul Sala, Eva Bustamante, Denisse Bretel, Oscar Arrieta, Andrés F. Cardona, Diogo A. Bastos
Publikováno v:
JCO Global Oncology, Vol , Iss 7, Pp 649-658 (2021)
PURPOSECOVID-19 has affected cancer care worldwide. Clinical trials are an important alternative for the treatment of oncologic patients, especially in Latin America, where trials can be the only opportunity for some of them to access novel and, some
Externí odkaz:
https://doaj.org/article/c6436c3390d04fb48eb100f0ab3f6c2c
Autor:
Tina Cascone, Cheuk H. Leung, Annikka Weissferdt, Apar Pataer, Brett W. Carter, Myrna C. B. Godoy, Hope Feldman, William N. William, Yuanxin Xi, Sreyashi Basu, Jing Jing Sun, Shalini S. Yadav, Frank R. Rojas Alvarez, Younghee Lee, Aditya K. Mishra, Lili Chen, Monika Pradhan, Haiping Guo, Ansam Sinjab, Nicolas Zhou, Marcelo V. Negrao, Xiuning Le, Carl M. Gay, Anne S. Tsao, Lauren Averett Byers, Mehmet Altan, Bonnie S. Glisson, Frank V. Fossella, Yasir Y. Elamin, George Blumenschein, Jianjun Zhang, Ferdinandos Skoulidis, Jia Wu, Reza J. Mehran, David C. Rice, Garrett L. Walsh, Wayne L. Hofstetter, Ravi Rajaram, Mara B. Antonoff, Junya Fujimoto, Luisa M. Solis, Edwin R. Parra, Cara Haymaker, Ignacio I. Wistuba, Stephen G. Swisher, Ara A. Vaporciyan, Heather Y. Lin, Jing Wang, Don L. Gibbons, J. Jack Lee, Nadim J. Ajami, Jennifer A. Wargo, James P. Allison, Padmanee Sharma, Humam Kadara, John V. Heymach, Boris Sepesi
Publikováno v:
Nature Medicine. 29:593-604
Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding ipilimumab to neoadjuvant N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc4d46457c34ffd4bc56a0716fe62bc7
https://doi.org/10.1038/s41591-022-02189-0
https://doi.org/10.1038/s41591-022-02189-0
Autor:
Xinyi Zhang, Frederico O. Gleber‐Netto, Shidan Wang, Roberta Rayra Martins‐Chaves, Ricardo Santiago Gomez, Nadarajah Vigneswaran, Arunangshu Sarkar, William N. William, Vassiliki Papadimitrakopoulou, Michelle Williams, Diana Bell, Doreen Palsgrove, Justin Bishop, John V. Heymach, Ann M. Gillenwater, Jeffrey N. Myers, Renata Ferrarotto, Scott M. Lippman, Curtis Rg Pickering, Guanghua Xiao
Publikováno v:
Cancer Medicine. 12:7508-7518
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a32162ac15932f426786a112689bcb95
https://doi.org/10.1002/cam4.5478
https://doi.org/10.1002/cam4.5478
Autor:
Gustavo Gössling, Taiane F. Rebelatto, Cynthia Villarreal-Garza, Ana S. Ferrigno, Denisse Bretel, Raul Sala, Juliana Giacomazzi, William N. William, Gustavo Werutsky
Publikováno v:
Current Oncology. 30:653-662
In Latin America and the Caribbean (LAC), progress has been made in some national and regional cancer control initiatives, which have proved useful in reducing diagnostic and treatment initiation delays. However, there are still significant gaps, inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b09984951795b7a71e8e79072f7ef52d
https://doi.org/10.3390/curroncol30010050
https://doi.org/10.3390/curroncol30010050
Autor:
William N. William, Jianjun Zhang, Xin Zhao, Edwin R. Parra, Naohiro Uraoka, Heather Y. Lin, S. Andrew Peng, Adel K. El‐Naggar, Jaime Rodriguez‐Canales, Jaejoon Song, Ann M. Gillenwater, Ignacio I. Wistuba, Jeffrey N. Myers, Kathryn A. Gold, Renata Ferrarotto, Patrick Hwu, Teresa Davoli, J. Jack Lee, John V. Heymach, Vassiliki A. Papadimitrakopoulou, Scott M. Lippman
Publikováno v:
Cancer. 129:714-727
Studies of the immune landscape led to breakthrough trials of programmed death-1 (PD-1) inhibitors for recurrent/metastatic head and neck squamous cell carcinoma therapy. This study investigated the timing, influence of somatic copy-number alteration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a76430949630ce38768c9b442fcf082d
https://doi.org/10.1002/cncr.34607
https://doi.org/10.1002/cncr.34607
Autor:
Edwin R. Parra, Pamela Villalobos, Carmen Behrens, Mei Jiang, Apar Pataer, Stephen G. Swisher, William N. William, Jiexin Zhang, Jack Lee, Tina Cascone, John V. Heymach, Marie-Andrée Forget, Cara Haymaker, Chantale Bernatchez, Neda Kalhor, Annikka Weissferdt, Cesar Moran, Jianjun Zhang, Ara Vaporciyan, Don L. Gibbons, Boris Sepesi, Ignacio I. Wistuba
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Abstract Background The clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor types, including lung
Externí odkaz:
https://doaj.org/article/a0fbee6e3c0d4cdda806783e081be8ef
Autor:
Zhi-Yuan Zhang, Chen-Ping Zhang, J. Jack Lee, Jeffrey N. Myers, Jiang Li, Li-Zhen Wang, Xiao Yang, Cheng-Zhe Yang, Jie Ma, Ying Liu, William N. William, Dong-Wang Zhu, Lai-Ping Zhong
PDF file - 746K, Forest plot of overall survival, disease-free survival, locoregional recurrence-free survival, and distant metastasis-free survival in OSCC patients treated with surgery and post-operative radiotherapy with and without TPF induction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69fbccf3b982e8515829817ad5274847
https://doi.org/10.1158/1535-7163.22501264.v1
https://doi.org/10.1158/1535-7163.22501264.v1
